title: Topiramate weight loss in migraine patients.
abstract: Topiramate (TPM) is generally recognized efficacious and safe in migraine prevention. A significant proportion of patients undergoing TPM administration may show weight loss. In epileptic subjects, high body mass index (BMI) was found to be predictive of weight loss under TPM therapy. We therefore aimed to study whether common clinical determinants may be associated to TPM weigh loss in migraine patients. In our clinical series, high BMI was not found a predictor of weight loss under TPM treatment. Unknown genetic and environmental factors that may determine the courses of weight loss under TPM therapy are still do be identified.
authors.affiliation: Neurology Unit, Department of Medical and Surgical Sciences, University of Brescia, Italy. antoalberici@yahoo.it
authors.forename: Antonella
authors.initials: A
authors.lastname: Alberici
authors.forename: Barbara
authors.initials: B
authors.lastname: Borroni
authors.forename: Filippo
authors.initials: F
authors.lastname: Manelli
authors.forename: Simona
authors.initials: S
authors.lastname: Griffini
authors.forename: Paola
authors.initials: P
authors.lastname: Zavarise
authors.forename: Alessandro
authors.initials: A
authors.lastname: Padovani
authors.forename: Giorgio
authors.initials: G
authors.lastname: Dalla Volta
mesh_terms: D000328:Adult; D015992:Body Mass Index; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016014:Linear Models; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D000077236:Topiramate; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D000077236:Topiramate; D005632:Fructose